Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
02 janv. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Attends Investor Events in December
30 nov. 2023 08h30 HE
|
Dyadic International, Inc.
Dyadic Attends Investor Events in December
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
29 nov. 2023 08h30 HE
|
Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
20 nov. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
08 nov. 2023 16h00 HE
|
Dyadic International, Inc.
Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme productsDYAI-100 Phase 1 clinical trial top-line...
Dyadic to Present at Industry Events in November
30 oct. 2023 08h30 HE
|
Dyadic International, Inc.
Dyadic to Present at Industry Events in November
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
25 oct. 2023 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Appoints Doug Pace to Its Executive Leadership Team
09 oct. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
05 oct. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Present at Industry and Investor Events in October
29 sept. 2023 08h30 HE
|
Dyadic International, Inc.
Dyadic to Present at Industry and Investor Events in October